Proinflammatory stimuli elicit rapid transcriptional responses via transduced signals to master regulatory transcription factors. To explore the role of chromatin-dependent signal transduction in the atherogenic inflammatory response, we characterized the dynamics, structure, and function of regulatory elements in the activated endothelial cell epigenome. Stimulation with tumor necrosis factor alpha prompted a dramatic and rapid global redistribution of chromatin activators to massive de novo clustered enhancer domains. Inflammatory super enhancers formed by nuclear factor-kappa B accumulate at the expense of immediately decommissioned, basal endothelial super enhancers, despite persistent histone hyperacetylation. Mass action of enhancer factor redistribution causes momentous swings in transcriptional initiation and elongation. A chemical genetic approach reveals a requirement for BET bromodomains in communicating enhancer remodeling to RNA Polymerase II and orchestrating the transition to the inflammatory cell state, demonstrated in activated endothelium and macrophages. BET bromodomain inhibition abrogates super enhancermediated inflammatory transcription, atherogenic endothelial responses, and atherosclerosis in vivo.
INTRODUCTION
Precise control of inflammation is essential for host defense. Defense against pyogenic infection requires rapid activation of tissue and circulating leukocytes and their recruitment by activated endothelium. However, inflammation is also integral to the pathophysiology of many common and life-threatening illnesses. Acute, high-grade inflammation accompanying sepsis features systemic inflammatory cell activation and contributes to multisystem organ failure and death (Medzhitov et al., 2012) . Chronic, low-grade inflammation is a pathogenic feature of autoimmune disorders as well as highly prevalent and morbid conditions such as diabetes mellitus and atherosclerosis (Libby et al., 2011) . As such, there is a pressing need to dissect inflammatory signaling for the elucidation of pathologic mechanisms of disease and the identification of targeted therapeutic interventions.
In inflammation, a primary mode of bidirectional cellular communication involves one set of cells releasing cytokines to activate surface receptors on effector cells. Transduced signals converge on activation and translocation of inflammatory transcription factors (Barnes and Karin, 1997) . A central pathway common to the interaction between activated leukocytes and endothelium is tumor necrosis factor alpha (TNF-a)-mediated signal transduction to nuclear factor-kappa B (NF-kB)-a family of master regulatory, proinflammatory transcription factors canonically defined by the p50/p65 heterodimer (Baltimore, 2011) . Following entry into the nucleus, NF-kB binds to DNA cis-regulatory elements at enhancers and promoters, prompting proinflammatory transcription (Pierce et al., 1988) .
Genome-bound nuclear NF-kB interacts with transcriptional coactivators to stimulate transcription at multiple steps including the remodeling of chromatin as well as the initiation and elongation of RNA polymerase II (RNA Pol II; Barboric et al., 2001; Kaikkonen et al., 2013; Natoli, 2009) . NF-kB recruits and interacts with defined chromatin regulators including histone acetyltransferases (P300), histone deacetylases, and epigenetic reader proteins, such as BRD4 (Ashburner et al., 2001; Huang et al., 2009; Zhong et al., 2002) . Through these interactions, NF-kB engages in crosstalk with chromatin remodeling machinery.
BRD4 is a member of the bromodomain and extraterminal domain (BET) family of transcriptional coactivators and elongation factors (BRD2, BRD3, BRD4, and BRDT; Dey et al., 2000; . Mechanistically, TNF-a or lipopolysaccharide (LPS) stimulation promotes direct acetylation of the p65 subunit (Lys310) of NF-kB by P300 , promoting a direct interaction with BRD4 through twin acetyl lysine-recognizing bromodomains (Huang et al., 2009 ). This interaction is needed for productive NF-kB transactivation (Huang et al., 2009) , suggesting a central role for BRD4 in inflammatory transcriptional signaling.
Prior research from our group and others has identified that BET bromodomains localize genome-wide to promoter and enhancer regions (Anand et al., 2013; Chapuy et al., 2013; Lové n et al., 2013; Nicodeme et al., 2010) . The majority of enhancerbound BRD4 is found within a small number of massive enhancer regions termed super enhancers (SE). Like locus control regions or stretch enhancers, SEs concentrate chromatin-bound coactivators to genes essential for specialized cellular function (i.e., immunoglobulin production in plasma cells), and lineage specification (i.e., germinal center differentiation; Chapuy et al., 2013; Lové n et al., 2013; Parker et al., 2013; Whyte et al., 2013) . Disruption of SE function by a first acetylated lysine-competitive small molecule BET bromodomain inhibitor from our group known as JQ1 (Filippakopoulos et al., 2010) suggests the mutability of these large chromatin structural elements (Chapuy et al., 2013) . However, the role of SEs in the control of dynamic cell state transitions remains unknown. Recently, BET bromodomain inhibition has been shown to abrogate global, maladaptive transcriptional programs during sepsis and heart failure, implicating BRD4 in stress-induced cell state transitions (Anand et al., 2013; Nicodeme et al., 2010) . These data provided a rationale for investigating the collaborative roles of NF-kB and BRD4 in regulating SEs during proinflammatory activation.
The endothelium is critical to the initiation and propagation of inflammation. Endothelial cells (ECs) prompt leukocyte recruitment, adhesion, and trafficking into tissues, thus mediating responses essential for many inflammatory disorders, including atherogenesis, in which activation of ECs is pathogenic (Gimbrone et al., 1990; Ley et al., 2007) . Despite these important roles in disease, global studies of chromatin structure and function in vascular endothelium have to date not been undertaken. In this study, we investigate the role of BRD4 in determining the inflammatory activation of ECs through NF-kB and SE formation. Here, we provide evidence that EC activation by the archetypal proinflammatory stimulus TNF-a rapidly deploys NF-kB to enhancers and promoters genome-wide, where it recruits BRD4. Through the recruitment of BRD4, NF-kB establishes new SEs coincident with the surprising, rapid redistribution of BRD4 away from endothelial resting state SEs. Newly established NF-kB SEs are proximal to and drive canonical genes of the inflammatory response in ECs, including key effectors of chemotaxis, adhesion, migration, and thrombosis. BRD4 depletion from chromatin through small molecule BET bromodomain inhibition impedes NF-kBdirected SE reorganization. The failure to form proinflammatory SEs preferentially suppresses SE-dependent proinflammatory gene transcription, translating into functional suppression of key TNF-a-induced endothelial responses of leukocyte rolling, adhesion, and transmigration. In vivo, we find that BET bromodomain inhibition suppresses atherogenesis-a pathogenic process predicated on inflammatory endothelial activation. Together, these data establish BET bromodomain-containing proteins as key effectors of the integrated mammalian inflammatory response through their rapid, dynamic, global reorganization of SEs during NF-kB activation and suggest SE targeting during inflammatory cell state transitions as a therapeutic approach.
RESULTS p65 and BRD4 Establish Super Enhancers during Proinflammatory Stimulation
To explore the role of NF-kB, BRD4, and SEs in the acute inflammatory activation of ECs, we activated NF-kB in primary human umbilical vein ECs with TNF-a, a canonical proinflammatory stimulus, for one hour. As expected, TNF-a resulted in NF-kB nuclear translocation ( Figures 1A and 1B) , a rapid change in EC state characterized by increased monocyte adhesion (Figure 1C) , and induction of adhesion molecule gene expression including E-selectin (SELE) and vascular cell adhesion molecule (VCAM1; Figure 1D ; Ley et al., 2007) . The recognized capacity of BRD4 to bind acetylated NF-kB (Huang et al., 2009) , suggests a coactivator role for the BET family in the robust p65-mediated EC inflammatory response observed. We therefore used chromatin immunoprecipitation coupled with high-throughput genome sequencing (ChIP-seq) to define p65 and BRD4 genomic occupancy in ECs before and following acute proinflammatory activation.
In TNF-a-stimulated ECs, p65 enrichment was evident at promoters (17.5%), intragenic (45.8%), and intergenic regulatory sequences (36.7%; Figures 1E and 1F ). Striking colocalization of BRD4 and p65 was observed by global enrichment alignment and binding site motif analysis ( Figure 1F ; Figure S1A available online). TNF-a treatment prompts dynamic colocalization of p65 and BRD4 to enhancer and promoter regions marked by H3K27ac, which are significantly enriched for p65 consensus sequences ( Figure S1A ; Matys et al., 2006) . At the exemplary VCAM1 locus, TNF-a stimulation of resting ECs for one hour increased p65 occupancy at both promoters and upstream enhancer elements marked by acetylated chromatin (H3K27ac; Figure 1G ). Coincident with these events, we identified recruitment of exceptionally high levels of BRD4 at discrete hyperacetylated enhancer elements (Figures 1F and 1G ; Figure S1B ), consistent with the formation of de novo SEs (SEs). Focal BRD4 colocalization with p65 was observed at each discrete peak, with complete concordance. Comparable evidence is provided at the SELE locus, where TNF-a stimulation recruits p65 and high levels of BRD4 to a gene regulatory region completely devoid of p65 and BRD4, augmenting regional hyperacetylation ( Figure S1C ). The dramatic remodeling of these loci in one hour in TNF-a stimulated ECs corroborates the robust transcriptional activation of these canonical EC inflammatory gene products ( Figure 1D ). Notably, typical enhancers are found at most other EC genes as exemplified by endothelial tyrosine kinase (TEK) and serpin peptidase inhibitor clade H1 (SERPINH1), where the levels of p65 and BRD4 are an order of magnitude lower compared to the VCAM1 or SELE SE; and TNF-a does not induce mRNA expression ( Figure 1H ; Figures S1D and S1E) .
To assess the genome-wide distribution of SEs during the EC inflammatory cell state transition, we characterized and compared the enhancer landscape in resting and TNF-a-activated ECs using BRD4 ChIP-seq data sets. When ranked by increasing BRD4 enrichment, 347 and 271 SEs were identified in resting and TNF-a-activated ECs, respectively. These SEs comprised $7% of the total number of discrete EC enhancer loci (Figure 2A ; Figure S2A ), but represented more than one-fourth of the total amount of enhancer size and more than one-third of enhancerbound BRD4 (Figures 2A and 2B ). Compared to typical enhancers, SE loci are significantly larger in DNA length, total BRD4 signal, and signal density and share less overlap between resting and TNF-a-activated ECs ( Figure 2C ; Figures S2A and  S2B) . Following TNF-a stimulation, the absolute change in BRD4 total signal and density at SEs was greater compared to typical enhancers ( Figure 2D ; Figure S2C ). We observed higher Figure S1 .
p65 total binding signal and density at SE loci when compared to either typical enhancer regions or active gene transcriptional start sites ( Figure 2E ; Figure S2D) . As exemplified by the VCAM1 SE locus and also observed globally, ECs feature dense clustering of multiple regulatory transcription factor binding sites known to be involved in EC proinflammatory responses including p65, p50, ETS1/2, and transcription factor 3/4 (TCF3/4; Figure 2F ; Figure S2E ; De Val et al., 2008; Masckauchá n et al., 2005) . In contrast, typical enhancer sites typified by the TEK locus possess a much lower density of these motifs ( Figure 2G ; Figure S2E ). To dissect the temporal relationship between p65 and BRD4 localization to enhancers, we next performed time-ranging chromatin binding studies. ChIP for p65 and BRD4 followed by real-time PCR centered on the most prominent NF-kB binding site in the 5 0 VCAM1 and CCL2 SEs revealed enrichment of p65 five minutes after TNF-a stimulation, with peak occupancy detected by 30 min ( Figure 2H ; Figure S2F ). BRD4 recruitment followed the identical temporal pattern of recruitment at these sites. Inhibition of NF-kB phosphorylation and function by IkB kinase inhibition (BAY 11-7082, ''BAY'') (Pierce et al., 1997) completely abrogated TNFa-induced p65 and BRD4 accumulation at both NF-kB sites at all time points, while also suppressing VCAM1 gene induction ( Figure S2G ). As expected, cotreatment of ECs with JQ1 reduced TNF-a-induced enrichment of BRD4 at these NF-kB binding sites. However, in contrast to BAY, JQ1 had no effect on immediate early p65 recruitment ( Figure 2H ; Figure S2F ). Compared to SEs, typical enhancers featured less TNF-a-induced recruitment of both NF-kB and BRD4 ( Figure 2H ; Figure S2F ). Collectively, these results establish that p65 is required for TNF-a-induced recruitment of BRD4 to SE regions in ECs. (C) Boxplots of median enhancer length (kb), signal (rpm), and density (rpm/bp) in TNF-a-gained enhancers. Significance of the difference between distributions determined using a two-tailed t test. ***p < 1 3 10 À10 .
(D) Boxplot of absolute change in BRD4 signal in response to TNF-a measured at all enhancers in TNF-a(À) and TNF-a(+). Significance of the difference between distributions determined using a two-tailed t test. ***p < 1 3 10 À10 .
(E) Boxplot of p65 binding signal (rpm) at all active gene promoters (TSS), TEs, and SEs in TNFa-treated ECs. Significance of the difference between distributions determined using a two-tailed t test. **p < 1 3 10 À5 , ***p < 1 3 10 
NF-kB Provokes Rapid Global Redistribution of BRD4 at Super Enhancers
We next explored the dynamics and function of SEs in inflammation in both ECs and macrophages. One hour following TNF-a stimulation, we observed the formation of pronounced, prototypical SEs at canonical inflammatory genes, such as the CCL2 chemokine ( Figure 3A ). There, a density of upstream and intragenic enhancer elements was identified, characterized by regional hyperacetylation (H3K27ac) and peaks of BRD4 enrichment coinciding with focal p65 binding sites ( Figure 3A) . Functionally, rapid SE formation was associated with recruitment of RNA Pol II ( Figure 3A ) and marked transcriptional activation ( Figure S3A ). These data provide a demonstration that the canonical proinflammatory stimulus TNF-a rapidly induces de novo formation of SEs established by p65 at proinflammatory target genes, also including VCAM1 and SELE ( Figures 1G and  S1C) .
Unexpectedly, the enrichment of BRD4 at inflammatory EC SEs was associated with the rapid, reciprocal depletion of BRD4 at resting EC SEs. ECs grown in culture feature 347 canonical SEs, including SEs associated with genes critical for noninflammatory EC function, such as the SOX18 transcription factor implicated in vasculogenesis (Matsui et al., 2006) . In such resting ECs, regional enrichment for H3K27ac is observed Figure S3 .
at the SOX18 locus, accompanied by characteristic BRD4 occupancy and evident enrichment for RNA Pol II throughout the gene body. In the inflammatory EC state, TNF-a fails to drive NF-kB to the SOX18 locus, RNA Pol II enrichment is markedly diminished and transcription is muted ( Figure 3B ; Figure S3A) . Only 1 hour following TNF-a stimulation, BRD4 is effectively depleted, despite persistent hyperacetylation (H3K27ac) of the SOX18 SE ( Figure 3B) .
To explore the relevance of changes in SEs provoked by proinflammatory activation across the genome, a systematic analysis of dynamic alterations in SE formation was undertaken. BRD4 enrichment was selected here as a preferred marker for SE identity owing to a concern that H3K27ac, or other more biochemically stable enhancer modifications (such as H3K4me1/2), may lag behind BRD4 redistribution globally in a dynamic cell state change, as above at the SOX18 locus. We identified a dramatic redistribution of genomic BRD4 occupancy following TNF-a stimulation ( Figure 3C ). Differential enhancer analysis revealed an evident global balance in chromatin-associated BRD4, but importantly TNF-a stimulation resulted in the reclassification of multiple enhancers from typical enhancer to SE (N = 152) and from SE to typical enhancer (N = 124; Figure 3C ). Gains in BRD4 occupancy were strongly and directly associated with site-specific increases in p65 binding occupancy genome-wide ( Figure 3D ). As expected, TNF-a-gained SEs are characterized by coordinate increases in BRD4 and H3K27ac enrichment at regions of increased p65 occupancy, which correlates directly with SE formation ( Figures 3C and S3B) . Consistent with the SOX18 regulatory region, lost SEs are defined by a significant reduction of BRD4 occupancy following TNF-a stimulation that is disproportionate to minimal changes in p65 and modest reductions in H3K27ac ( Figures 3D and S3C) . Finally, the p65 motif was found at much higher density in TNF-a-gained versus TNF-a-lost SEs regions in ECs, further suggesting p65 direct binding to clustered sites in TNF-a-gained SEs as a causal event in BRD4 SE redistribution during inflammatory activation ( Figure 3E ), akin to comparable ''stretch enhancers'' as described by Francis Collins and colleagues (Parker et al., 2013) .
NF-kB-Formed Super Enhancers Drive Proinflammatory Transcription
To assess the consequences of SE redistribution on transcriptional output, we integrated genome-wide ChIP-seq data with cell count-normalized, array-based absolute gene expression profiling measurements obtained before and 1 hour after TNF-a stimulation. Compared to typical and conserved enhancer regions, the gain or loss of SEs provoked by TNF-a resulted in the largest changes to RNA Pol II occupancy and expression of adjacent genes ( Figures 4A and 4B ). This global relationship was also evident when specifically comparing the change in the levels of SE constituent BRD4 versus change in nearby gene elongating RNA Pol II levels and expression (Figures 4C and 4D ). Those genes positioned near TNF-aÀgained SEs, which also feature BRD4 enrichment at their promoters suggestive of promoter-enhancer communication, demonstrated marked induction of transcriptional initiation, elongation, and gene expression ( Figure 4E ; Figure S4A ). Functional classification of TNF-a-gained SE marked genes reveals known drivers of key functional facets of EC inflammatory responses: cytokine signaling, chemotaxis, adhesion and migration, and thrombosis ( Figure 4G ; Figure S4F ). In contrast, the reciprocal loss of BRD4 at resting EC SEs resulted in a proportionate decrease in transcription and expression of nearby genes (Figures 4A, 4B , and 4F), such as THBD and genes involved in angiogenesis and endothelial barrier function ( Figure 4H ; Figure S4G) . Notably, the cohort of lost SE genes featured marked decreases in transcriptional initiation and elongation by RNA Pol II enrichment metagene analysis in advance of changes in promoter modification (H3K4me3 enrichment; Figure S4B ). Genes with conserved enhancers show minimal change in expression and serve pathways that govern homeostatic function in ECs (Figures 4A and 4B; Figure S4H ). Globally, this chromatin restructuring results in a strong induction of proinflammatory SE driven transcription compared to typical enhancer associated genes. The 62 TNF-a-gained, SE-associated genes comprise only $8% of all genes with >2-fold increase in mRNA expression, but account for $60% of the total increase in upregulated gene expression and $20% of the increase in cellular mRNA within 3 hr of TNFa stimulation (Figures S4C-S4E ). These data provide discrete examples and global evidence of dynamic, functional remodeling of enhancer factors even preceding the structural decommissioning of abandoned enhancers.
NF-kB-Formed Super Enhancers Drive Proinflammatory
Gene Expression in a BET Bromodomain-Dependent Manner Disruption of SEs by disrupting enhancer factors, such as BRD4, has been observed to selectively influence the expression of genes associated with SEs (Lové n et al., 2013). In cancer, we have observed that competitive displacement of BET bromodomains from nuclear chromatin provokes coordinated inhibition of the MYC transcriptional program, often associated with downregulation of MYC itself (Chapuy et al., 2013; Delmore et al., 2011; Zuber et al., 2011) . Using a chemical genetic approach, we assessed the role of BET bromodomains in the rapid transcriptional response of SE-associated, proinflammatory genes in TNFa-stimulated ECs. Small molecule probes, such as the BET bromodomain inhibitor JQ1, are particularly appealing in the study of dynamic processes, because they offer precise temporal perturbation of the biological system (Frye, 2010; Strausberg and Schreiber, 2003) . We therefore performed a dynamic, genome-wide analysis of BET bromodomain inhibition on inflammatory SE integrity, global chromatin structure, gene expression, and EC postinflammatory function.
First, we characterized the effect of JQ1 on EC chromatin structure and function immediately following TNF-a exposure. ECs were treated with JQ1 (500 nM) to displace BET bromodomains, then stimulated with TNFa for 1 hour. Chromatin from treated and untreated ECs was subjected to ChIP-seq for promoters (H3K4me3), enhancers (H3K27ac), RNA Pol II, the p65 transcription factor, and the BRD4 coactivator. At the SELE locus, BET inhibition had no effect on TNF-a-mediated recruitment of p65 ( Figures 5A and 5B) . However, JQ1 depleted BRD4 resulting in abrogated SELE expression assessed by decreased RNA Pol II enrichment ( Figure 5A and cell surface protein levels assessed by flow cytometry ( Figure S5E ). Comparable observations are evident at the CCL2 and IRAK2 loci, where BET inhibition selectively displaces BRD4 leading to impaired transcription induction and elongation by RNA Pol II (Figures S5A and S5B) .
Global analysis of TNF-a-stimulated ECs revealed preferential loss of BRD4 at TNF-a-gained SEs compared to typical enhancers, with minimal effect on TNFa-induced p65 binding or H3K27ac levels ( Figure 5B ). TNF-a-gained SEs possessed a diminished capacity to drive proinflammatory transcription initiation and elongation in the presence of the BRD4 inhibitor, JQ1 ( Figure 5C ), and these dynamic effects on RNA Pol II enrichment were independent of alterations in promoter modification by differential metagene analysis of H3K4me3 enrichment at the transcriptional start sites ( Figure S5C ). Functionally, preferential JQ1-induced loss of transcription at TNF-a-gained SEassociated genes culminated in more potent suppression of their proinflammatory gene expression program relative to genes driven by typical enhancers ( Figure 5C ; Figure S5D ). Treatment of ECs with TNF-a and JQ1 suppressed the maximal mRNA induction of SE-associated genes (FS3, CCL2, VCAM1) at a lower concentration of JQ1 and to a greater degree compared to TE-associated genes (LOX, TEK, NLRP1; Figure 5D ). Together, these data support a model in which BET bromodomains mediate dynamic and immediate inflammatory EC response gene transcription, by facilitating chromatin-dependent signal transduction from NF-kB to RNA Pol II.
To determine whether JQ1 transcriptional effects resulted from specific engagement of BETs at nuclear chromatin, we spatially localized the JQ1 molecule genome-wide using a new biotechnology called Chem-seq (Anders et al., 2014) . This technique maps the interactions of small molecules with chromatin in the human genome, in this instance by using a retrievable synthetic derivative of JQ1 (biotin-JQ1). Notably, despite high levels of acetylated HK27ac at enhancers, we detected no biotin-JQ1 occupancy with Chem-seq at SELE and other SEs ( Figure 5E ; Figures S5F and S5G ) in resting ECs. Rather, at these loci, biotin-JQ1 binding to chromatin perfectly colocalized with BRD4 spatially and temporally following TNF-a-stimulation. Genome-wide analysis demonstrated a dose-dependent relationship between biotin-JQ1 localization and the decrease in genomic BRD4 occupancy, not H3K27ac, in ECs treated with TNF-a + JQ1 compared to TNF-a alone ( Figures 5F and 5G) . Taken together, these data reveal that JQ1 directly targets BRD4 during proinflammatory activation in ECs. Preferential loss of BRD4 at inflammatory SEs by BET bromodomain inhibition serves mechanistically to underscore the observed selective effects on transcription.
To assess the generalizability of these observations, we tested whether the BRD4-dependent formation of proinflammatory SEs is relevant for other immune effector cells. We integrated robust, publically available acetyl-histone data (H4K12ac) with RNA Pol II ChIP-seq data in LPS-stimulated macrophages (Nicodeme et al., 2010) , to map SEs and explore the effect of BET inhibition on enhancer-mediated transcriptional signaling. H4K12ac is a histone mark defining active enhancers that can be used to identify SEs in the absence of specific enhancer coactivator data Whyte et al., 2013) .
Large gains of histone acetylation were identified in macrophages following LPS stimulation at the Irak2 proinflammatory gene locus ( Figure S6A ). LPS treatment provoked an immediate increase in promoter and intergenic acetylation, accompanied by an increase in RNA Pol II enrichment throughout the gene body. Globally, SE analysis identified 122 gained SEs following LPS treatment near proinflammatory genes involved in cytokine signaling, cell adhesion, and chemotaxis ( Figures S6B and S6C) . Unlike inflammatory ECs, the target genes induced and associ- ated with proinflammatory SEs in macrophages are largely distinct from those found in ECs ( Figure S6D ). Transcription at SE-associated genes was more strongly induced by LPS compared to genes controlled by typical enhancers, as revealed by composite analysis of RNA Pol II enrichment and elongation ( Figures S6E and S6F) . As in activated ECs, BET bromodomain inhibition in macrophages preferentially suppressed transcription of genes driven by proinflammatory SEs as compared to genes controlled by typical enhancers ( Figures  S6G and S6H ). The Irak2 locus provides an exemplary illustration of the effect of BET bromodomain inhibition using the structurally analogous I-BET inhibitor (Nicodeme et al., 2010) , on depletion of RNA Pol II enrichment ( Figure S6A ). Collectively, these data from ECs and macrophages demonstrate that proinflammatory SEs drive proinflammatory gene activation in a cell context specific manner.
BET Bromodomain Inhibition Suppresses Leukocyte Rolling, Adhesion, and Transmigration in Endothelium
In response to proinflammatory stimuli, endothelial-leukocyte interactions follow a sequential cascade involving leukocyte chemoattraction, their slow rolling, and subsequent firm adhesion to ECs, culminating in leukocyte endothelial transmigration into tissue (Ley et al., 2007) . To explore a phenotypic effect of SE disruption by BET bromodomain inhibition, we tested the functional effects of JQ1 on leukocyte rolling across TNF-a-activated endothelium in vivo. C57Bl/6 mice were pretreated with JQ1 (50 mg/kg) 12 hours before TNF-a injection. As depicted with intravital microscopy of leukocyte rolling in the cremaster postcapillary venule, BET bromodomain inhibition significantly reduced the leukocyte rolling flux (15.8 versus 7.5, p < 0.01; Figure 6A ) and the number of leukocyte rollers/minute (42.8 versus 25.14, p < 0.05; data not shown), without changing systemic white blood cell count or shear stress ( Figure S7A ). BET bromodomain inhibition also shifted the distribution of leukocyte velocity and increased mean velocity (2.89 mm/s versus 3.91 mm/s, p < 0.01), consistent with an effect on E-selectin-mediated slow rolling ( Figures 6B and 6C) .
Next, we examined firm adhesion of the human monocytic cell line (THP1) to activated ECs in vitro. TNF-a-stimulated ECs had significantly increased numbers of attached THP1 cells (Figure 6D ). JQ1 pretreatment of ECs suppressed THP1 adhesion to TNF-a-activated ECs by 70% ( Figures 6D and 6E) . Similarly, siRNA inhibition of BRD4 expression in ECs recapitulated JQ1's effects on THP1 adhesion to ECs (Figures 6F and 6G ). Lastly, we tested BET bromodomain inhibitor effects on leukocyte transmigration in a parallel-plate flow chamber. TNF-a stimulation of ECs resulted in transmigration of 67% of human neutrophils (Figure 6H) . Pretreatment of ECs with JQ1 prior to TNF-a stimulation reduced neutrophil transmigration in a concentration-dependent manner ( Figure 6H ). In kinetic studies of transcription response of TNF-a-stimulated ECs, JQ1 demonstrated prolonged inhibitory effects on expression of SE-associated genes (SELE, VCAM1, CXCL8, CCL2) over 48 hr ( Figures 6I-6L ). These data establish BET bromodomain inhibition as a functional suppressor of the phenotypic features of EC proinflammatory activation.
BET Bromodomain Inhibition Suppresses Atherogenesis in Hypercholesterolemic Mice
Proinflammatory activation of ECs is a seminal, early event in atherogenesis, a process driven by vascular inflammation that also involves monocytes/macrophages and precedes atherosclerosis (Cybulsky et al., 2001) . The transcriptional and functional effects of BET bromodomain inhibition in ECs prompted us to examine their role in atherogenesis using the well-established low-density lipoprotein (LDL) receptor-deficient (Ldlr À/À ) mouse model. Vehicle-treated mice fed a cholesterol-enriched diet (10 weeks) developed atherosclerosis, as measured by oil red O staining ( Figure 7A ). Once-daily JQ1 treatment (50 mg/ kg) reduced aortic plaque area by 40% ( Figure 7A ). Notably, there was no difference in LDL and high-density lipoprotein cholesterol between the vehicle and JQ1 treatment groups (168 versus 164 mg/dL and 56 versus 59 mg/dL, respectively; total cholesterol 911 versus 1,349 mg/dl; see also Table S6 .). Early atherosclerotic lesions are comprised of macrophages (98%-99%) with lesser amounts of T lymphocytes (1%-2%). Mac-3 staining demonstrated that JQ1 treatment significantly lowered total macrophage staining area, CD4-positive T lymphocytes, and levels of VCAM1 protein (Figures 7B-7D ). Oil red O staining of en face thoracoabdominal aortas revealed decreased atherosclerotic plaque beyond the aortic root ( Figures 7E and  7F) . Soluble VCAM1 and ICAM1 levels were also significantly reduced in JQ1-treated animals compared to vehicle ( Figures  S7B and S7C) , suggesting an effect of BET bromodomain inhibition on systemic proinflammatory activation in vivo. We next tested whether BET bromodomain inhibition mitigated the activation of proadhesion pathways in aortic endothelium, which occurs during the first 10 weeks of exposure to an atherogenic diet. In ex vivo aortic adhesion assays, the aortas harvested from animals (6 weeks on diet) treated with JQ1 supported less adhesion of fluorescently labeled monocytes ( Figures S7D and S7E ). These data demonstrate BET inhibition significantly decreased atherogenesis and accumulation of inflammatory cells in a well-characterized murine model of atherosclerosis.
DISCUSSION
The inflammatory response underlies numerous chronic diseases. NF-kB is a master regulatory transcription factor in several dominant inflammatory signaling cascades, which cooperate with chromatin-associated regulatory complexes to direct inflammatory transcription (Natoli, 2009) . Enhancer-bound NFkB arises following nuclear translocation in a manner influenced by pioneer transcription factors (Kaikkonen et al., 2013; Natoli, 2009; Ostuni et al., 2013 ) and a preestablished topology that places distal enhancer regions and target genes in spatial proximity (Jin et al., 2013) . Here, we explore the role of chromatin in terminal signal transduction from NF-kB to RNA polymerase, specifically at massive regulatory regions.
Super or stretch enhancers represent less than 5% of the enhancers in a cell, yet they use almost half of all enhancer coactivator proteins (Lové n et al., 2013; Parker et al., 2013; Whyte et al., 2013) and are highly transcribed, producing large amounts of enhancer RNA that may itself facilitate target gene activation Kaikkonen et al., 2013) . The SE landscape is remarkably cell-type specific, driving expression of the genes that define and maintain cell identity in different tissues and cell lineages. The present study demonstrates that NF-kB engages most endothelial enhancers following proinflammatory activation, yet significant BRD4 recruitment to form de novo SEs is restricted to a subset of these enhancer regions. NFkB-directed SE formation causes global reorganization of the BRD4 SE landscape and induces the transcription of many canonical proinflammatory endothelial genes. Whereas previous studies have studied the importance of SEs in the maintenance of cell identity , here we describe de novo SE formation as a mechanism by which stimulus-coupled master regulatory transcription factors such as NF-kB can coordinate a rapid transcriptional response that drives a dynamic change in cell state.
This study of kinetic transcriptional response during the inflammatory cell state transition in ECs unexpectedly identified a rapid loss of SEs upon cytokine stimulation. As orchestrated by the master regulatory inflammatory transcription factor NF-kB, SE formation comes at the immediate expense of SEs associated with active transcription of genes in unstimulated ECs, including targets involved in cell specification and noninflammatory cell states. Many of these lost SE associated genes, such as SOX18, will be downregulated. Curiously, we find persistent marks of open, active euchromatin at the SOX18 locus (H3K27ac), yet BRD4 depletion is associated with loss of RNA pol II transcription. In studies of dynamic cell state transitions, as here, we find that experimental measurements of canonical enhancer marks (i.e., H3K27ac, H3K4me1/2) are inferior to assessments of enhancer coactivators (i.e., BRD4) for characterizing rapid changes in enhancer structure and function. As such, BRD4 may be viewed and used as a rheostat for enhancer output, converting typical enhancers into SEs, thereby driving rapid and robust induction of inflammatory transcription.
In our previous studies, genes with the highest occupancy of BRD4 at their proximal SEs were the most selectively downregulated by BET bromodomain inhibition (Chapuy et al., 2013; Lové n et al., 2013) . However, these studies characterized effects on cells at ground state, where stable, preestablished SEs predominate. During cell state transitions, such as the present study of EC and macrophage activation, we observe potent and selective effects on upregulated genes associated with de novo SEs. Preferential disruption of dynamic SEs by BET bromodomain inhibition abrogates the induction of inflammatory transcription. The direct relationship between BRD4 enrichment and transcription suggests that modulating BRD4 levels at enhancers may influence the pathogenesis of inflammatory diseases. Changes in eRNA levels by NF-kB-directed BRD4 SE formation may also be an important factor in proinflammatory transcription in ECs, but await future study. Further granularity on dynamic enhancer remodeling will accompany progress in genome-wide enhancer detection and assignment.
In many disease settings, the degree of the host inflammatory response is a key determinant of severity (Medzhitov et al., 2012) . Here we show small molecule BET bromodomain inhibition (JQ1) significantly attenuated endothelial activation during acute inflammation in vitro and ex vivo, as revealed by suppression of TNF-a induced leukocyte rolling, adhesion and transmigration. Finally, in a hypercholesterolemic murine model of atherosclerosis, in which EC proinflammatory activation is a seminal early event, 10-week treatment with JQ1 suppressed cardinal histopathologic features of atherogenesis. These data in vascular endothelial activation establish a critical and early role for BET bromodomains in dynamic enhancer remodeling. They describe a mechanism for rapid inflammatory gene activation by NF-kBmediated formation of SEs. Taken in the context of prior research in macrophage activation, spermatogenesis, and myocyte hypertrophy (Anand et al., 2013; Delmore et al., 2011; Matzuk et al., 2012; Nicodeme et al., 2010) , these data support a model where localization of BET bromodomains to chromatin facilitates cell state transitions. The existence of BET bromodomain inhibitors provides, then, a broad opportunity for inflammatory gene control through modulation of chromatin structure and function.
